AZD-1705 is under clinical development by AstraZeneca and currently in Phase I for Dyslipidemia. According to GlobalData, Phase I drugs for Dyslipidemia have a 68% phase transition success rate (PTSR) ...

Solbinsiran sodium is under clinical development by Eli Lilly and Co and currently in Phase II for Mixed Dyslipidemia. According to GlobalData, Phase II drugs for Mixed Dyslipidemia have a 74% phase ...

particularly for patients with familial hypercholesterolemia (FH), mixed dyslipidemia or statin intolerance. Several nonstatin drugs, including ezetimibe, nicotinic acid and fibrates, have been ...

[133] Several classes of drugs are available for the management of dyslipidemia.

This review examines the cardiovascular risks associated with cannabis, revealing its potential to cause severe heart health ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

“Beneficial pediatric obesity treatment response yielded enduring health benefits, markedly lowering future morbidity and mortality risks in young adulthood,” the authors write. Several authors ...

Sometimes you may receive a combination of therapies, or something else entirely. Oncology (cancer) drugs include a range of therapies and medications, such as chemotherapy drugs, targeted ...

When children with obesity undergo weight-loss treatment, the results have effects later in life, and the risk of serious ...

Traditionally, dyslipidemia is often defined by elevated levels of total cholesterol (TC), low ... personalized treatment strategies, evaluations of drug efficacy and toxicity, as well as drug target ...

Paralytic drugs, or neuromuscular blocking agents (NMBAs), are powerful muscle relaxants used to prevent muscle movement during surgical procedures. They're also used during critical care, such as ...